AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
https://www.zacks.com/stock/news/2280785/astrazeneca-azn-falls-on-failure-to-meet-nsclc-study-os-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2280785
May 29, 2024 - AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.
0
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
https://www.fool.com/investing/2024/05/29/astrazeneca-just-massively-one-upped-pfizer-heres/?source=iedfolrf0000001
May 29, 2024 - Both businesses have road maps for the future, but one is better.
0
Why Astrazeneca (AZN) is a Great Dividend Stock Right Now
https://www.zacks.com/stock/news/2277424/why-astrazeneca-azn-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-2277424
May 22, 2024 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
0
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
https://www.zacks.com/stock/news/2272954/bristol-myers-bmy-fails-to-meet-goal-in-opdivo-nsclc-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2272954
May 13, 2024 - Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
0
Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates
https://www.zacks.com/stock/news/2272308/ironwood-irwd-q1-earnings-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2272308
May 10, 2024 - Ironwood (IRWD) incurs loss in the first quarter of 2024. Revenues decline year over year and miss estimates. The company lowers revenue guidance for 2024. Stock falls.
0
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
https://www.zacks.com/stock/news/2272178/why-astrazeneca-azn-is-a-top-growth-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_growth_score-2272178
May 10, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
Why Astrazeneca (AZN) is a Top Dividend Stock for Your Portfolio
https://www.zacks.com/stock/news/2268918/why-astrazeneca-azn-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-2268918
May 06, 2024 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
0
Top Analyst Reports for AstraZeneca, QUALCOMM & FedEx
https://www.zacks.com/commentary/2267832/top-analyst-reports-for-astrazeneca-qualcomm-fedex?cid=CS-ZC-FT-research_daily-2267832
May 03, 2024 - Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), QUALCOMM Incorporated (QCOM) and FedEx Corporation (FDX).
0
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
https://www.zacks.com/stock/news/2262673/astrazeneca-azn-q1-earnings-sales-beat-estimates-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2262673
Apr 25, 2024 - AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.
0
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/04/25/astrazeneca-plc-azn-q1-2024-earnings-call-transcri/?source=iedfolrf0000001
Apr 25, 2024 - AZN earnings call for the period ending March 31, 2024.
0